Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
Autor: | Pradip De, J. Jack Lee, Michael E. Hahn, Shumei Kato, Hitendra Patel, Jason K. Sicklick, Brian Leyland-Jones, Jessica Guido, Benjamin M. Solomon, Mina Nikanjam, Scott M. Lippman, Paul T. Fanta, Casey Williams, Sarah Boles, Rana R. McKay, Razelle Kurzrock, Jeffrey S. Ross, Ryosuke Okamura, Amy Krie |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male Oncology N of 1 trial medicine.medical_specialty Personalized medicine.medical_treatment QH426-470 Therapy naive Young Adult Stable Disease Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Genetics medicine Humans Molecular Targeted Therapy Prospective Studies Prospective cohort study Adverse effect Molecular Biology Genetics (clinical) Aged business.industry Research Genomics Targeted Immunotherapy Middle Aged Precision Combined Modality Therapy Clinical trial Medicine Molecular Medicine Immunohistochemistry Female business |
Zdroj: | Genome Medicine Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021) |
ISSN: | 1756-994X |
Popis: | Background Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be feasible and efficacious. Patients with newly diagnosed unresectable/metastatic, poor-prognosis cancers were enrolled in a cross-institutional prospective study. Methods A total of 145 patients were included in the study. Genomic profiling (tissue and/or circulating tumor DNA) was performed in all patients, and PD-L1 immunohistochemistry, tumor mutational burden, and microsatellite status assessment were performed in a subset of patients. We evaluated safety and outcomes: disease-control rate (stable disease for ≥ 6 months or partial or complete response), progression-free survival (PFS), and overall survival (OS). Results Seventy-six of 145 patients (52%) were treated, most commonly for non-colorectal gastrointestinal cancers, carcinomas of unknown primary, and hepatobiliary malignancies (53% women; median age, 63 years). The median number of deleterious genomic alterations per patient was 5 (range, 0–15). Fifty-four treated patients (71%) received ≥ 1 molecularly matched therapy, demonstrating the feasibility of administering molecularly matched therapy. The Matching Score, which reflects the percentage of targeted alterations, correlated linearly with progression-free survival (R2 = 0.92; P = 0.01), and high (≥ 60%) Matching Score was an independent predictor of improved disease control rate [OR 3.31 (95% CI 1.01–10.83), P = 0.048], PFS [HR 0.55 (0.28–1.07), P = 0.08], and OS [HR 0.42 (0.21–0.85), P = 0.02]. Serious adverse event rates were similar in the unmatched and matched groups. Conclusions Personalized combination therapies targeting a majority of a patient’s molecular alterations have antitumor activity as first-line treatment. These findings underscore the feasibility and importance of using tailored N-of-1 combination therapies early in the course of lethal malignancies. Trial registration I-PREDICT (NCT02534675) was registered on August 25, 2015. |
Databáze: | OpenAIRE |
Externí odkaz: |